loading page

Mechanisms of Enzalutamide Resistance in Castration-Resistant Prostate Cancer and Therapeutic Strategies to Overcome It
  • +4
  • Yuanyuan Wang,
  • Jiyuan Chen,
  • Zhengjie Wu,
  • Weihong Ding,
  • Shen Gao,
  • Yuan Gao,
  • Chuanliang Xu
Yuanyuan Wang
Fudan University

Corresponding Author:[email protected]

Author Profile
Jiyuan Chen
Fudan University
Author Profile
Zhengjie Wu
Changhai Hospital
Author Profile
Weihong Ding
Huashan Hospital Fudan University
Author Profile
Shen Gao
Changhai Hospital
Author Profile
Yuan Gao
Fudan University School of Pharmacy
Author Profile
Chuanliang Xu
Changhai Hospital
Author Profile


Prostate cancer (PCa) is the second most common malignancy in men, and androgen deprivation therapy (ADT) is the first-line therapy. However, most cases will eventually develop into castration-resistant prostate cancer (CRPC) after ADT treatment. Enzalutamide (Enz) is a second-generation androgen receptor inhibitor approved by the Food and Drug Administration to treat patients with CRPC. Unfortunately, patients receiving Enz treatment will ultimately develop resistance via various complicated mechanisms. In this review, we introduce the emerging information on resistance mechanisms, including androgen receptor-related signalling pathways, glucocorticoid receptor-related pathways, and metabolic mechanisms. Notably, lineage plasticity and phenotype switching, gene polymorphisms, and the relationship between microRNAs and drug resistance are addressed. Furthermore, potential therapeutic strategies for Enz-resistant CRPC treatment are suggested, which can help in the discovery of more effective and specific regimens to overcome Enz resistance.
25 Jul 2020Submitted to British Journal of Pharmacology
27 Jul 2020Submission Checks Completed
27 Jul 2020Assigned to Editor
03 Aug 2020Reviewer(s) Assigned
20 Sep 2020Review(s) Completed, Editorial Evaluation Pending
28 Sep 2020Editorial Decision: Revise Minor
14 Oct 20201st Revision Received
19 Oct 2020Submission Checks Completed
19 Oct 2020Assigned to Editor
19 Oct 2020Reviewer(s) Assigned
20 Oct 2020Review(s) Completed, Editorial Evaluation Pending
22 Oct 2020Editorial Decision: Accept
Jan 2021Published in British Journal of Pharmacology volume 178 issue 2 on pages 239-261. 10.1111/bph.15300